Article Listing - Genzyme's 4th-qtr sales climb 21%, beating forecasts; predicts EPS of $7 by 2011
Australia's revised code to benefit ASX-listed life science companies
16 May 2013
Australia's Minister for Technology, Gordon Rich-Phillips, this week joined forces with the Australian Securities Exchange (ASX) and Australia's biotechnology industry association, AusBiotech, to launch a revised edition of the industry code of best practice that will support capital formation by ASX-listed life science companies.
Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
16 May 2013
Merck Serono, a division of Germany's Merck KGaA (MRK: DE), announced detailed results from the randomized Phase III START trial of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC), showing the drug failed to meet its primary endpoint.
US FDA approves Janssen's Simponi to treat ulcerative colitis
16 May 2013
The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Ortho Biotech's Simponi (golimumab) injection, to treat adults with moderate to severe ulcerative colitis.
Strong initial data on Genentech's obinutuzumab in most common blood cancer
16 May 2013
Genentech, the biotech subsidiary of Swiss drug major Roche Group (ROG: SIX), has announced positive first results from CLL11, a Phase III study of the investigational drug obinutuzumab (GA101), which is being conducted in collaboration with the German CLL Study Group (GCLLSG).
Europe adopting US strategies to diagnose and treat ADHD
16 May 2013
The impending publication of the fifth edition of the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM-V) later this month may affect diagnosis rates of conditions such as attention-deficit hyperactivity disorder (ADHD), both in the USA and worldwide, says new analysis by GBI Research.
US Senate confirms appointment of Marilyn Tavenner as CMS Administrator
16 May 2013
US Health and Human Services (HHS) Secretary Kathleen Sebelius announced that the US Senate has confirmed Marilyn Tavenner as Administrator of the Centers for Medicare & Medicaid Services (CMS).
Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo
16 May 2013
The US Food and Drug Administration yesterday (May 15) approved Xofigo (radium Ra 223 dichloride, initially called Alpharadin), from German drug major Bayer (BAYN: DE), to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer.
Merck Serono and Quintiles enter novel clinical development partnership
16 May 2013
Merck Serono, the biotech division of Germany's Merck KGaA (MRK: DE) and Quintiles (NYSE: Q) have announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well-aligned clinical development engine, the German firm says. Financial terms of the accord were not revealed.
AstraZeneca plans to move three cancer drug candidates into Ph III
16 May 2013
Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning (May 16) announced that it will be moving three of its cancer compounds: moxetumomab pasudotox, olaparib and selumetinib into Phase III clinical development.
FDA approves Arbor Pharma's Nymalize for use in certain brain hemorrhage patients
15 May 2013
Privately-held US firm Arbor Pharmaceuticals says that the US Food and Drug Administration has approved its New Drug Application for Nymalize (nimodipine) oral solution, marking the first NDA approval for the company.
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
